New ultrasound contrast agent could spot liver cancer sooner
NCT ID NCT07590284
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test whether using a contrast agent called Sonazoid during ultrasound can find early-stage liver cancer better than standard ultrasound alone. About 556 adults with liver cirrhosis will be scanned every 4 to 6 months. The goal is to see if this method catches more cancers at an early, treatable stage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sonazoid contrast agent for ultrasound
- What this could lead to
- If successful, this could improve early detection of liver cancer in high-risk patients, potentially saving lives through earlier treatment.
- What could go wrong
- This is an early-stage diagnostic study, not a treatment trial. The new method may not prove more effective than current imaging, and results may not apply to all liver disease patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Third Central Hospital
Tianjin, Tianjin Municipality, 300170, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- A new procedure may offer relief for Cirrhosis-Related fluid buildup
- Can extra doses of an old drug reverse liver scarring?
- Can liver damage predict how drugs behave?
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Better crystal ball for liver crisis: new scores put to the test